| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Fourth quarter revenue increased 12% to $59.9 billion Fourth quarter GAAP1 operating earnings were $401 million and GAAP diluted EPS was $0.96 Fourth quarter non-GAAP operating earnings increased...
Cardinal Health (NYSE: CAH) plans to release fourth-quarter and year-end financial results for its fiscal year 2024 on August 14, prior to the opening of trading on the New York Stock Exchange....
Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved an increase to its quarterly dividend, to $0.5056 per share, out of the Company's capital surplus. The dividend...
Read more about Cardinal Health Board of Directors Approves Increase to Quarterly Dividend
Revenue increased 9% to $54.9 billion GAAP1 operating earnings were $367 million; GAAP diluted EPS was $1.05 Non-GAAP operating earnings increased 10% to $666 million; non-GAAP diluted EPS...
Cardinal Health (NYSE: CAH) announced today that its pharmaceutical distribution contracts with OptumRx, which expire at the end of June 2024, will not be renewed. The company reaffirmed its...
The Consumer Health Logistics Center will be located in Central Ohio and serve as a centralized hub for distribution of consumer health products COLUMBUS, Ohio, April 2, 2024 /PRNewswire/ --...
Cardinal Health (NYSE: CAH) plans to release third-quarter financial results for its fiscal year 2024 on May 2, prior to the opening of trading on the New York Stock Exchange. The company will...
Read more about Cardinal Health to Announce Third-Quarter Results for Fiscal Year 2024 on May 2
Cardinal Health (NYSE: CAH) today announced that the company has received approval by the Science Based Targets initiative (SBTi) for its near-term science-based greenhouse gas (GHG) emissions...
Study reveals impact of dramatic increase in commercially available biosimilars and progress in the areas of patient accessibility and treatment affordability DUBLIN, Ohio, Feb. 29, 2024...
Read more about Cardinal Health annual research report examines milestone year in biosimilars
Cardinal Health (NYSE: CAH) announced today that its Board of Directors has elected Robert "Bob" Azelby as an independent director, effective March 1. Mr. Azelby joins the board with over 30 years...
Read more about Bob Azelby to join Cardinal Health Board of Directors
Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved a quarterly dividend of $0.5006 per share out of the Company's capital surplus. The dividend will be payable on...
Read more about Cardinal Health Board of Directors Approves Quarterly Dividend
Cardinal Health (NYSE: CAH) today released its Fiscal 2023 Environmental, Social and Governance (ESG) Report, highlighting the company's work toward building a healthier, more equitable future....
Revenue increased 12% to $57.4 billion GAAP1 operating earnings were $482 million; GAAP diluted EPS was $1.43 Non-GAAP operating earnings increased 20% to $562 million; non-GAAP diluted EPS...
Transaction creates increased clinical and economic value for 11,500 specialty providers, including more than 7,000 physicians across 1,200 independent physician practices Transaction creates...
Progress achieved on company's ongoing business and portfolio review Completed review of growth businesses within the Medical Segment: investing in and further developing at-Home Solutions and...
Cardinal Health (NYSE: CAH) plans to release second-quarter financial results for its fiscal year 2024 on February 1, prior to the opening of trading on the New York Stock Exchange. The company...
Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved a quarterly dividend of $0.5006 per share out of the Company's capital surplus. The dividend will be payable on...
Read more about Cardinal Health Board of Directors Approves Quarterly Dividend
SmartGown™ EDGE is the first pocketed surgical gown designed to help maintain instrument sterility and accessibility. DUBLIN, Ohio, Nov. 9, 2023 /PRNewswire/ -- Cardinal Health (NYSE: CAH)...
Revenue increased 10% to $54.8 billion GAAP1 operating loss was $14 million and GAAP diluted EPS was $0.02, driven by a Medical segment goodwill impairment Non-GAAP operating earnings increased 35% to
Read more about The Harvard Drug Group, LLC Issues Voluntary Nationwide Recall of Certain Rugby® Laboratories Brand Eye Drops Supplied by Velocity Pharma, LLC Due to Potential Risk of Eye Infections
Read more about Cardinal Health, Inc. Issues Voluntary Nationwide Recall of Certain LEADER™ Brand Eye Drops Supplied by Velocity Pharma, LLC Due to Potential Risk of Eye Infections
Cardinal Health (NYSE: CAH) has been named among the 100 Best Corporate Citizens, a prestigious annual ranking by 3BL Media that assesses the environmental, social and governance (ESG)...
Read more about Cardinal Health Named to 100 Best Corporate Citizens of 2023
The next generation in enteral feeding, Kangaroo OMNI™ delivers nutrition and hydration from hospital to home. DUBLIN, Ohio, Sept. 28, 2023 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced...
Read more about Cardinal Health Launches Kangaroo OMNI™ Enteral Feeding Pump
Cardinal Health (NYSE: CAH) plans to release first-quarter financial results for its fiscal year 2024 on November 3, prior to the opening of trading on the New York Stock Exchange. The company...
Read more about Cardinal Health to Announce First-Quarter Results for Fiscal Year 2024 on November 3
Cardinal Health Foundation will invest $1.7M to help 14 children's hospitals nationwide prevent youth suicide. DUBLIN, Ohio, Sept. 13, 2023 /PRNewswire/ -- Cardinal Health (NYSE: CAH) in...